ABSTRACT

The present invention is directed to compounds represented by the formula (1):

B-D-Z (1), wherein B represent the following formula (B-1), (B-2) or (B-3);

$$(R_1) \text{ in } (R_2) \text{ in } (R_3) \text{ in } (R_1) \text{ in } (R_2) \text{ in } (R_3) \text{ in } (R_2) \text{ in } (R_3) \text{ in }$$

A represents an optionally substituted imidazole or pyrazole group;

E represents the following formula (1a);

$$\begin{array}{c|c}
 & R_{\beta 0} \\
\hline
 & N \\
\end{array}$$

$$\begin{array}{c|c}
 & R_{7} \\
\hline
 & C \\
\end{array}$$

$$\begin{array}{c|c}
 & R_{7} \\
\hline
 & R_{8} \\
\end{array}$$
(1a)

X represents an oxygen atom, the formula: SOu, or the formula: N-R₉;

Y represents a carbon atom or a nitrogen atom;

D represents an oxygen atom, a sulfur atom or the formula (1a);

Z represents (a chroman-2-yl group, a chroman-4-yl group, a 2,3-dihydrobenzofuran-2-yl group, a 2,3-dihydrobenzofuran-3-yl group, etc.) which is substituted with NHR₁₀ or OR₁₁)] or pharmaceutically acceptable salts thereof, and to antioxidants, therapeutic agents for kidney diseases or cerebrovascular disorder, and retinal oxidative damage inhibitors, which include the compounds as the active ingredient.